Cancer

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 years ago

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Rapid, robust, and clinically significant reduction in depression symptomsTrials of MB22001 show substantial improvements in mood, energy, creativity, wellbeing, depression…

2 years ago

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet…

2 years ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…

2 years ago

Nusano to Host Virtual Event “Office Hours: Radiopharmaceuticals” on June 28, 2024

VALENCIA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today announced…

2 years ago

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain…

2 years ago

Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Application (NDA)…

2 years ago

Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors

Planegg/Martinsried, June 20, 2024. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the…

2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on…

2 years ago